BIOMAT Database Logo BIOMAT Database Logo

Mutation covariation of HIV-1 CRF07_BC reverse transcriptase during antiretroviral therapy. 2013

Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention (NCAIDS), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese Center for Disease Control and Prevention (China-CDC), Beijing 102206, China.

OBJECTIVE To understand the effect of HIV-1 drug resistance mutations in the context of antiretroviral therapy (ART), we compared the prevalence of protease (PR) and reverse transcriptase (RT) mutations in HIV-1 CRF07_BC sequences from blood samples of treatment-naive and ART-treated patients. METHODS Mutation covariation in the RT and PR of HIV-1 CRF07_BC viruses from 542 treatment-naive patients and 261 patients treated with lamivudine/zidovudine/nevirapine or lamivudine/zidovudine/efavirenz was analysed. Stratified networks were used to display the mutation covariation. RESULTS Based on the comparison between treatment-naive and ART-treated patients, three types of featured mutations for RT and PR were initially identified: treatment-associated mutations, treatment-agonistic mutations and overlapping polymorphisms. Twelve significant covariation pairs were found between five treatment-associated mutations (K103N, M184V, Q197K, G190A and Y181C) and nine overlapping polymorphisms (A36E, D39N, Y121H, D123E, R135I, T200A, R277K, L283I and D291E). Meanwhile, three covariation pairs between three treatment-associated mutations (I132L and M184V for RT and I15V for PR) and three overlapping polymorphisms (L10I, L36M and A71V) for PR were also detected. Finally, the overlapping polymorphisms for RT and PR were both found to have significant correlations with treatment-associated mutations, indicating a possible association between polymorphisms and drug resistance. When compared with HIV-1 subtype B under the same regimens as CRF07_BC, the mutation covariations of CRF07_BC showed a distinct pattern of RT and PR mutation covariation. CONCLUSIONS The role of polymorphisms in the development of drug resistance has been widely reported. Here, we found a significant correlation between overlapping polymorphisms for RT and PR and treatment-associated mutations, indicating that polymorphisms exert a global influence on treatment-associated mutations. Polymorphism mutations might therefore be considered before initiating ART to improve the efficacy of drug combinations.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III
D044966 Anti-Retroviral Agents Agents used to treat RETROVIRIDAE INFECTIONS. Antiretroviral Agent,Antiretroviral Agents,Agent, Antiretroviral,Agents, Anti-Retroviral,Agents, Antiretroviral,Anti Retroviral Agents
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D020125 Mutation, Missense A mutation in which a codon is mutated to one directing the incorporation of a different amino acid. This substitution may result in an inactive or unstable product. (From A Dictionary of Genetics, King & Stansfield, 5th ed) Missense Mutation,Missense Mutations,Mutations, Missense
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
HIV-1 subtype B protease and reverse transcriptase amino acid covariation.
May 2007, PLoS computational biology,
Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
The K65R mutation in HIV-1 reverse transcriptase.
May 2004, Journal of HIV therapy,
Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient.
May 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
Antiretroviral therapy: reverse transcriptase inhibition.
February 1992, Antimicrobial agents and chemotherapy,
Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
February 2013, Antimicrobial agents and chemotherapy,
Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
March 2002, Antiviral therapy,
Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
Long-term efficacy of dual nucleoside reverse transcriptase inhibitor antiretroviral therapy in HIV-1 infection.
July 2002, AIDS (London, England),
Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy.
December 2002, AIDS research and human retroviruses,
Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
HIV-1 reverse transcriptase dissociates during strand transfer.
September 2011, Journal of molecular biology,
Zhenpeng Li, and Yang Huang, and Yabo Ouyang, and Hui Xing, and Lingjie Liao, and Shibo Jiang, and Yiming Shao, and Liying Ma
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
August 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!